Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (2014 - 2026)

Lexaria Bioscience has reported Net Income towards Common Stockholders for 13 years, with the latest figure at $2.0 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 47.37% year-over-year to $2.0 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $7.7 million (down 32.46% YoY) and the FY2025 annual result came in at $11.9 million, up 105.17% from the prior year.
• Net Income towards Common Stockholders rose to $2.0 million in Q2 2026 per LEXX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $3.8 million in Q2 2025 and troughed at -$2.4 million in Q2 2022.
• A 5-year average of $1.3 million and a median of $1.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders jumped 452.82% in 2022, then sank 53.85% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.8 million in 2022, then soared by 168.34% to $1.2 million in 2023, then soared by 125.0% to $2.7 million in 2024, then plunged by 40.74% to $1.6 million in 2025, then climbed by 25.0% to $2.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $2.0 million, $1.4 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.